A pooled analysis of quality of life measures and adverse events data in North Central Cancer Treatment Group lung cancer clinical trials

Cancer

Volumn 109, Issue 4, 2007, Pages 787-795

  Huschka, Mashele M ^a   Mandrekar, Sumithra J ^a   Schaefer, Paul L ^b   Jett, James R ^a   Sloan, Jeff A ^a  

^a MAYO CLINIC   (United States)

^b Toledo Comm Clin Oncology Program   (United States)

Author keywords

Adverse events; Lung cancer; Pooled analysis; Quality of life

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; ADVERSE DRUG REACTION; AGED; ALOPECIA; ANOREXIA; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DATA ANALYSIS; DIARRHEA; DISEASE SEVERITY; DYSPNEA; FATIGUE; FEMALE; FUNCTIONAL ASSESSMENT FOR CANCER THERAPY LUNG; HUMAN; KAPLAN MEIER METHOD; LUNG CANCER; LUNG CANCER SYMPTOM SCALE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; POOLED DATA ANALYSIS; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; SELF REPORT; SENSORY DYSFUNCTION; SYMPTOM DISEASE SCALE; UNISCALE; UNITED STATES; VOMITING;

ACTIVITIES OF DAILY LIVING; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ENDPOINT DETERMINATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; QUALITY OF LIFE; RADIOTHERAPY; SICKNESS IMPACT PROFILE;

EID: 33846924355     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22444     Document Type: Article

References (38)

1. Osoba DA. Taxonomy of the uses of health-related quality-of-life instruments in cancer care and the clinical meaningfulness of the results. Med Care. 2002;40:31-38.
2. Sloan JA, Loprinzi CL, Kuross SA, et al. Randomized comparison of four tools measuring overall quality of life in patients with advanced cancer. J Clin Oncol. 1998;16:3662-3673.
3. Sloan JA, Aaronson N, Cappelleri JC, et al. Assessing the clinical significance of single items relative to summated scores. Mayo Clin Proc. 2002;77:479-487.
4. Cox DR, Fitzpatrick R. Quality-of-life assessment: can we keep it simple? J R Stat Soc. 1992;155:353-393.
5. Goodwin PJ, Black JT, Bordeleau LJ, et al. Health-related quality of life measurement in randomized clinical trials in breast cancer: taking stock. J Natl Cancer Inst. 2003;95:263-281.
6. Frost MH, Sloan JA. Quality of life measurements: a soft outcome - or is it? Am J Managed Care. 2002;8:S574-S579.
7. Chassany O, Sagnier P, Marquis P, et al. Patient-reported outcomes: the example of health-related quality of life - a European guidance document for the improved integration of health-related quality of life assessment in the drug regulatory process. Drug Info J. 2002;36:209-238.
8. Spitzer WO, Dobson AJ, Hall J, et al. Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. J Chronic Dis. 2001;34:585-597.
9. Grunberg SM, Groshen S, Steingass S, et al. Comparison of conditional quality of life terminology and visual analogue scale measurements. Quality Life Res. 1996;5:65-72.
10. Gudex C, Dolan P Kind P, et al. Health state valuations from the general public using the visual analogue scale. Quality Life Res. 1996;5:521-531.
11. Hyland ME, Sodergren SC. Development of a new type of global quality of life scale and comparison and preference for 12 global scales. Quality Life Res. 1996;5:469-480.
12. Sriwatanakul K, Kelvie W, Lasagna L, et al. Studies with different types of visual analog scales for measurement of pain. Clin Pharmacol Ther. 1983;34:234-239.
13. Wewers ME, Lowe NK. A critical review of visual analogue scales in the measurement of clinical phenomena. Res Nurs Health. 1990;13:227-236.
14. De Boer AGEM, van Lanschot JJB, Stalmeier PFM, et al. Is a single-item visual analogue scale as valid, reliable and responsive as multi-item scales in measuring quality of life? Quality Life Res. 2004;13:311-320.
15. Goddard G, Karibe H, McNeill C. Reproductivity of visual analog scale (VAS) pain scores to mechanical pressure. J Craniomandibular Pract. 2004;22:250-256.
16. Hollen P, Gralla R, Kris M, Potanovich L. Quality of life assessment in individuals with lung cancer: testing the lung cancer symptom scale. Eur J Cancer. 1993;29:S51-S58.
17. Hollen PJ, Gralla RJ. Comparison of instruments for measuring quality of life in patients with lung cancer. Semin Oncol. 1996;23:31-40.
18. McCorkle R, Young K. Development of a symptom distress scale. Cancer Nurs. 1978;1:373-378.
19. McCorkle R, Benoliel JQ. Symptom distress, current concerns, and mood disturbances after diagnosis of life threatening disease. Soc Sci Med. 1983;17:431-438.
20. Cella DF, Bonomi AE, Lloyd SR, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer. 1995;12:199-220.
21. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13:176-181.
22. Hillman SL, Mandrekar SJ, Bot BM, et al. Should attribution be considered when interpreting adverse event data: a North Central Cancer Treatment Group (NCCTG) evaluation of a Phase III placebo controlled trial. [abstract]. J Clin Oncol. 2006;24(18S):6006.
23. Sloan JA, Dueck A. Issues for statisticians in conducting analyses and translating results for quality of life end points in clinical trials. J Biopharm Stat. 2004;14:73-96.
24. Sloan JA, Vargas-Chanes D, Kamath CC, et al. Detecting worms, ducks and elephants: a simple approach for defining clinically relevant effects in quality-of-life measures. J Cancer Integrative Med. 2003;1:41-47.
25. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003;41:582-592.
26. Sloan JA, Cella D, Hays R. Clinical significance of patient-reported questionnaire data: another step toward consensus. J Clin Epidemiol. 2005;58:1217-1219.
27. Bland JM, Altman DG. Comparing two methods of clinical measurement: a personal history. Int J Epidemiol. 1995;24:s7-sl4.
28. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307-310.
29. Mandrekar SJ, Huschka MM, Schaefer PL, Jett JR, Adjei AA, Sloan JA. What is the value added of patient reported outcomes relative to physician rated symptom assessments? [abstract]. J Clin Oncol. 2006;24(18S):8580.
30. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawerence Earlbaum Associates; 1988.
31. Morton RF, Sloan JA, Grothey A, et al. A comparison of simple single-item measures and the common toxicity criteria in detecting the onset of oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer. [abstract]. J Clin Oncol. 2005;23(16S):8087.
32. Lee H, Friedman ME, Cukor P, Ahern D. Interactive voice response system (IVRS) in health care services. Nurs Outlook. 2003;51:277-283.
33. Weiler K, Christ AM, Woodworth GG, et al. Quality of patient-reported outcome data captured using paper and interactive voice response diaries in an allergic rhinitis study: is electronic data capture really better? Ann Allergy Asthma Immunol. 2004;92:335-339.
34. Bonner JA, Sloan JA, Hillman SL, et al. A Phase II study of high dose twice-daily thoracic radiation therapy with concomitant cisplatin/etoposide in limited stage small cell lung cancer. [abstract]. Proc Am Soc Clin Oncol. 2001;20. Abstract 1260.
35. Colon-Otero G, Niedringhaus RD, Hillman SL, et al. A Phase II trial of edatrexate, vinblastine, Adriamycin, cisplatin and filgrastim (EVAC/G-CSF) in patients with advanced non-small cell carcinoma of the lungs: an NCCTG trial. Am J Clin Oncol. 2001;24:551-555.
36. Johnson EA, Marks RS, Mandrekar SJ, et al. A Phase III randomized placebo controlled NCCTG trial of carboxyaminoimidazole (CAI) in patients with advanced non-small cell lung cancer. [abstract]. J Clin Oncol. 2005;23(16S): 7054.
37. Okuno SH, Delaune R, Sloan JA, et al. Gemcitabine and epirubicin in patients with malignant pleural mesothelioma. [abstract]. J Clin Oncol. 2005;23(16S):7264.
38. Kanard A, Jatoi A, Castillo RA, et al. Oral vinorelbine for the treatment of metastatic non-small cell lung cancer in elderly patients: a Phase II trial of efficacy, toxicity, and patients' preference for oral therapy. Lung Cancer. 2004;43:345-353.